Ticagrelor Intermediates CAS 376608 71 8 C9H9F2N C8H8O3 cGMP Standard

CAS : 376608-71-8 Ticagrelor Intermediate C9H9F2N C8H8O3

Chemical Name : ( 1R , 2S ) - 2 - ( 3 , 4 - difluorophenyl ) cyclopropanamine ( S ) - 2 - hydroxy - 2 - phenylacetate

CAS No . : 376608-71-8

Synonyms :  ( 1R , 2R ) - 2 - ( 3 , 4 - difluorophenyl )cyclopropanamine ( S ) - ( carboxylato ( phenyl ) methyl) holmium

Molecular Formula : C17H17F2NO3 ; C9H9F2N . C8H8O3

Molecular Weight : 321.32

Usuage: Ticagrelor Intermediate

Description: Ticagrelor is the active pharmaceutical ingredients (API) of branded drug Brillinta, Briliquie and Possia. It was approved in December 3 2010 in Euorpe and in July 2011in USA by FDA . It is marketed by AstraZeneca. Ticagrelor is a platelet aggregation inhibitor and used to prevent thrombotic events such as stroke or heart attack in people with acutate coronary syndrome or myocardial infarction with ST elevation. Ticagrelor is better than clopidogrel for P2Y12 inhibition treatment in patients with NSTE-ACS treated with early invasive strategy and/or coronary stenting according to AHA/ACC Guidelines (09/2014).

( 1R , 2S ) - 2 - ( 3 , 4 - difluorophenyl ) cyclopropanamine ( S ) - 2 - hydroxy - 2 - phenylacetate CAS No . : 376608-71-8 is one of Ticagrelor intermediates. Ticagrelor is protected by some patents in some countries and areas such as USA, Europe and China. We strictly obey the laws and our product is only for R&D purpose. The buyers should determine the patent status and take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.